- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07507760
고령/허약한 성인 급성 골수성 백혈병 환자를 위한 1차 치료제로서 경구 데시타빈과 이보시데닙 병용 요법 (DECISIVO)
신규 진단 급성 골수성 백혈병 환자 중 60세 이상 및/또는 표준 유도 화학요법이 적합하지 않은 성인 환자를 대상으로 경구용 데시타빈과 이보시데닙 병용 요법의 유효성과 안전성을 평가하는 2상, 다기관, 개방형 임상시험
The goal of this clinical trial is to learn if the combination of oral decitabine plus ivosidenib works to treat naïve adult patients with acute myeloid leukemia (AML) with IDH1 R132 mutation older than 60 years old or those who are older than 18 years old with defined comorbidities that make them not suitable for standard induction therapy. The main objectives of this clinical trial are:
- Asses the Complete Remission (CR) and Complete Remission with incomplete marrow recovery (CRi) rates of this treatment.
- Determine the incidence and severity of all adverse events (AEs).
All participants will receive oral ivosidenib and oral decitabine in treatment cycles of 28 days until disease progression, lack of clinical benefit or the end of the study. Patients who achieve CR/CRi will be elegible to receive allogeneic stem cell transplantation.
연구 개요
상태
상세 설명
A total of 50 participants will be assigned to the single treatment arm which will have treatment cycles of 28 days with Ivosidenib 500 mg/orally on Days 1-28 plus oral decitabine-cedazuridine (one tablet once daily containing 35 mg decitabine and 100 mg cedazuridine as a fixed-dose combination) on days 1-5.
Hydroxiurea or maximum 1 gram/sqm of cytarabine is allowed to control hyperleukocytosis during the screening period as well as during the first two cycles of induction.
Participants will continue their study treatment until documented disease progression per Investigator assessment, unacceptable toxicity, withdrawal of consent, the subject meets other protocol criteria for discontinuation or study completion (whichever occurs first).
Participants who are considered eligible for an allogeneic stem cell transplant after achieving CR/CRi will perform a pre-transplant visit into the study, collecting MRD stats and characteristics of transplant. They will be allowed to resume ivosidenib after day +60 of transplant. The post-transplant schedule can be administered for up to 2 years. If they do not resume ivosidenib they will perform end of trial visit (and if this is not possible the pre-transplant visit will be considered as en of trial visit).
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Pau Montesinos
- 전화번호: +34 96 1244925
- 이메일: montesinos_pau@gva.es
연구 연락처 백업
- 이름: Juan José Lahuerta
- 이메일: jjlahuerta@telefonica.net
연구 장소
-
-
-
Albacete, 스페인, 02006
- 아직 모집하지 않음
- Complejo Hospitalario de Albacete
-
수석 연구원:
- Jesús Lorenzo Algarra Algarra
-
Alicante, 스페인
- 아직 모집하지 않음
- Hospital General Universitario Dr. Balmis
-
수석 연구원:
- Carmen Botella, Dr
-
Burgos, 스페인, 09006
- 모병
- Hospital Universitario de Burgos
-
수석 연구원:
- Jorge Labrador
-
Cáceres, 스페인
- 모병
- Hospital San Pedro Alcántara
-
연락하다:
- Juan Bergua
-
Córdoba, 스페인, 14004
- 모병
- Complejo Hospitalario Regional Reina Sofía
-
수석 연구원:
- Josefina Serrano López
-
Las Palmas, 스페인
- 아직 모집하지 않음
- Hospital Universitario de Gran Canaria Doctor Negrín
-
연락하다:
- Carlos Rodríguez
-
Las Palmas de Gran Canaria, 스페인
- 아직 모집하지 않음
- Hospital Universitario de Canarias
-
수석 연구원:
- Carolina Lacalzada
-
Lugo, 스페인
- 아직 모집하지 않음
- Hospital Universitario Lucus Augusti
-
수석 연구원:
- Aitor Abuín, Dr
-
Madrid, 스페인
- 아직 모집하지 않음
- H. 12 de Octubre
-
연락하다:
- Pilar Martínez Sánchez
-
Madrid, 스페인, 28040
- 아직 모집하지 않음
- Fundación Jiménez Díaz
-
수석 연구원:
- José Luis López Lorenzo
-
Madrid, 스페인
- 아직 모집하지 않음
- Hospital Univeristario Ramón y Cajal
-
연락하다:
- Pilar Herrera
-
Málaga, 스페인
- 모병
- Hospital Virgen de la Victoria
-
연락하다:
- Maria García Fortes, Dr
-
Seville, 스페인
- 모병
- Hospital Universitario Virgen Del Rocío
-
연락하다:
- Eduardo Rodríguez Arbolí
-
수석 연구원:
- Eduardo Rodríguez Arbolí
-
Valencia, 스페인
- 아직 모집하지 않음
- H. Dr. Peset
-
연락하다:
- María José Sayas
-
부수사관:
- María Pedreño, MD
-
Valencia, 스페인
- 모병
- Hospital Universitari i Politècnic La Fe
-
수석 연구원:
- Irene Navarro
-
-
-
-
-
Aveiro, 포르투갈
- 아직 모집하지 않음
- ULS Região de Aveiro
-
연락하다:
- Cátia Sol dos Reis
-
Funchal, 포르투갈
- 아직 모집하지 않음
- Hospital Central do Funchal
-
연락하다:
- Rebeca Brito
-
Lisbon, 포르투갈
- 아직 모집하지 않음
- Hospital Santa Maria
-
연락하다:
- Joana Brioso
-
Lisbon, 포르투갈
- 아직 모집하지 않음
- ULS São José
-
연락하다:
- Luís Monteiro
-
Porto, 포르투갈
- 아직 모집하지 않음
- Hospital Pedro Hispano
-
연락하다:
- Ilídia Moreira
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Morphological diagnosis of AML (WHO criteria 2022)
-
Newly diagnosed AML.
-
IDH1 R132 mutations (centrally assessed by PCR and NGS). A patient will be allowed to be included with local result after approval of the medical monitor.
-
Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2 if ≥ 60 years of age, or 0 to 3 if ≥ 18 to 60 years.
-
Age ≥ 18 years with comorbidities contraindicating intensive chemotherapy; or age ≥ 60 years.
-
≥ 60 years of age;
-
or ≥ 18 to 60 with at least one of the following co-morbidities:
- ECOG Performance Status of 2 or 3;
- Cardiac history of CHF requiring treatment or Ejection Fraction ≤ 55% or chronic stable angina;
- DLCO ≤ 65% or FEV1 ≤ 65% or significant history of chronic pulmonary obstructive;
- Creatinine clearance ≥ 25 mL/min to < 50 ml/min
- Moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0 × ULN
- Non active/controlled prior neoplastic disease
- Any other patient´s comorbidity or disease condition that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the PETHEMA medical monitor before study enrolment (e.g, prior MDS or MPS, high-risk cytogenetics)
-
-
Patients <70 years, with favorable risk AML according to ELN will be included only if they are not candidates to standard treatment with intensive chemotherapy.
-
Adequate renal function as demonstrated by a creatinine clearance ≥ 25 mL/min (calculated by the Cockcroft Gault formula).
-
Adequate liver function as demonstrated by: aspartate aminotransferase (AST) ≤ 5.0 × ULN, alanine aminotransferase (ALT) ≤ 5.0 × ULN, bilirubin ≤ 2.5 × ULN (unless considered to be due to leukemic disease, in which case it should be approved by the PETHEMA medical monitor).
-
Subject has a white blood cell count < 30 × 109/L (Hydroxyurea is permitted to meet this criterion)
-
Female subjects must be either postmenopausal OR permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy) OR Women of Childbearing Potential (WOCBP) practicing at least one protocol specified method of birth control. Female subjects of childbearing potential must have negative results for pregnancy tests performed along the study (screening and every three cycles). A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.
-
Male subjects who are sexually active, must agree, from Study Day 1 through at least 90 days after the last dose of study drug, to practice the protocol specified contraception.
-
Subject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.
Exclusion Criteria:
- Subject has history of myeloproliferative neoplasm [MPN] with BCR-ABL1 translocation and AML with BCR-ABL1 translocation.
- Prior therapy for AML (except hydroxiurea).
- Genetic diagnosis of acute promyelocytic leukemia.
- Subject is known to be positive for HIV (HIV testing is not required.)
- Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months. (Hepatitis B or C testing is not required).
- Subject has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications including excipients that in the opinion of the investigator would adversely affect his/her participating in this study.
- Any severe uncontrolled systemic infection.
- Subject has a history of other malignancies within 1 year prior to study entry which is not controlled and/or requiring active therapy which may compromise the administration of IVO and oral decitabine.
- Creatinine clearance <25 mL/min (calculated by the Cockcroft-Gault formula).
- Inadequate liver function as demonstrated by AST or ALT > 5.0 × ULN, or bilirubin > 2.5 × ULN (unless considered to be due to leukemic disease, in which case it should be approved by the PETHEMA medical monitor)
- Subject has a white blood cell count > 30 × 109/L that is not controlled using hydrea or 1 gr/sqm/day per 1 day of cytarabine.
- Contraindications for IVO or oral decitabine according to the SmPC.
- Patient has a heart rate-corrected QT interval using Fridericia's method QT for corrected heart rate (QTcF) ≥450 msec or any other factor that increases the risk of QT prolongation or arrhythmic events (e.g., hypokalemia, family history of long QT interval syndrome). Patients with prolonged QTcF interval in the setting of bundle branch block may participate in the trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Decitabine+Ivosidenib
Participants will receive treatment cycles of 28 days with Ivosidenib 500 mg/orally on Days 1-28 plus oral decitabine-cedazuridine (one tablet once daily containing 35 mg decitabine and 100 mg cedazuridine as a fixed-dose combination) on days 1-5. Hydroxiurea or maximum 1 gram/sqm of cytarabine is allowed to control hyperleukocytosis during the screening period as well as during the first two cycles of induction. Participants who achieve CR/CRi can be submitted to allogeneic stem cell transplant and will be allowed to resume ivosidenib after day +60 of transplant. The post-transplant schedule can be administered for up to 2 years. |
Oral Decitabine (Decitabine/Cedazuridine 35 Mg-100 Mg) will be administerd on Days 1-5 of each treatment cycle Ivosidenib 500 mg/orally on Days 1-28 of each treatment cycle 0.5-6 gram/day orally during the screening period and the two first treatment cycles if hyperleukocytosis at diagnosis Maximum 1 gram/sqm/day during the screening period and the two first treatment cycles if hyperleukocytosis at diagnosis Only for those participants achieving CR/CRi |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Rate of CR/CRi
기간: 3 years
|
To assess the rates of Complete Remission (CR) and Complete Remission with incomplete marrow recovery (CRi) of participants treated with Ivosidenib plus Decitabine |
3 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Rate CR/CRi compared to historical cohort
기간: 3 years
|
To evaluate the CR (Complete Remission)/CRi (Complete Remission with incomplete marrow recovery) rates after 2, 3 and 6 cycles of Ivosidenib and oral Decitabine, and compare with a matched historical cohort. |
3 years
|
|
OS compared to historical cohort
기간: 3 years
|
To assess OS (overall survival, measured as the number of days from the date of enrollment to the date of death, whatever the cause of death) and compare the median between Ivosidenib with oral Decitabine and a matched historical cohort. |
3 years
|
|
EFS compared to historical cohort
기간: 3 years
|
To evaluate EFS (event-free survival, defined as the number of days from enrollment until the date of progressive disease, relapse from CR or CRi, failure to achieve CR or CRi, or death from any cause) and compare with a matched historical control cohort |
3 years
|
|
Hematologic and non-hematologic toxicity and AE
기간: 3 years
|
Toxicity and adverse events (AE) will be recorded and evaluated to determine treatment safety. Toxicity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.019. |
3 years
|
|
Quality of CR
기간: 3 years
|
The quality of the Complete Remission (CR) will measured by the study of minimal residual disease percentages in the bone marrow using multiparametric flow cytometry and Next Generation Sequencing |
3 years
|
|
Early mortality
기간: 3 years
|
To evaluate the mortality rate during the first 60 days of treatment |
3 years
|
공동 작업자 및 조사자
수사관
- 연구 의자: Pau Montesinos, Hospital Universitari i Politèncic La Fe
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- DECISIVO
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .